Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: A comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT)

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Fukao, Kosuke ^a   Shimada, Kazunori ^a   Hiki, Makoto ^a   Kiyanagi, Takashi ^a   Hirose, Kuniaki ^a   Kume, Atsumi ^a   Ohsaka, Hiromichi ^a   Matsumori, Rie ^a   Kurata, Takeshi ^a   Miyazaki, Tetsuro ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZELNIDIPINE; C REACTIVE PROTEIN; GLUCOSE; INSULIN; INTERLEUKIN 6; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DRUG DERIVATIVE;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; CELL FUNCTION; CLINICAL ARTICLE; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; STEM CELL; TONOMETRY; URINE; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADULT; AGED; AMLODIPINE; AZETIDINECARBOXYLIC ACID; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIHYDROPYRIDINES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEM CELLS;

EID: 80052559673     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-79     Document Type: Article

References (36)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332(7533):73-78. 10.1136/bmj.38678.389583.7C, 1326926, 16371403.
2. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1 c level. Diabetes Care 2000, 23(12):1830-1834. 10.2337/diacare.23.12.1830, 11128361.
3. Miyazaki T, Shimada K, Iwama Y, Kume A, Sumiyoshi K, Sato Y, Ohmura H, Watanabe Y, Mokuno H, Daida H. Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb 2008, 15(1):6-12. 10.5551/jat.E515, 18270458.
4. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342(13):905-912. 10.1056/NEJM200003303421301, 10738048.
5. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29(5):1065-1070. 10.2337/dc05-2366, 16644638.
6. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37(4):1053-1059.
7. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369(9557):201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
8. Yoshinaga K, Iimura O, Abe K, Saruta T, Kurokawa K, Ishii M. A multicenter double-blind comparison study of CS-905 (azelnidipine) with nitrendipine in patients with essential hypertension. Journal of Clinical Therapeutic Medicine 2000, 16:671-739.
9. Nishiya D, Enomoto S, Omura T, Matsumoto R, Kusuyama T, Izumi Y, Iwao H, Takeuchi K, Yoshiyama M. The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction. J Pharmacol Sci 2007, 103(4):391-397. 10.1254/jphs.FP0061139, 17409632.
10. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007, 333(6):321-326. 10.1097/MAJ.0b013e318065c254, 17570983.
11. Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K, et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J 2011, 75(5):1071-1079. 10.1253/circj.CJ-11-0141, 21471671.
12. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004, 43(5):724-730. 10.1097/00005344-200405000-00016, 15071361.
13. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, Ueda Y, Takeuchi M, Yamagishi S. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol 2011, 34(6):372-377. 10.1002/clc.20885, 21432860.
14. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, et al. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006, 319(3):1081-1087. 10.1124/jpet.106.108894, 16990512.
15. Kain V, Kumar S, Puranik AS, Sitasawad SL. Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol 2010, 9:82. 10.1186/1475-2840-9-82, 3004822, 21118576.
16. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009, 32(1):3-107.
17. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010, 1:2-20.
18. Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008, 58(4):990-1000. 10.1002/art.23287, 2820283, 18383391.
19. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44(11):2137-2141. 10.1016/j.jacc.2004.08.062, 15582310.
20. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008, 31(5):982-988. 10.2337/dc07-1768, 18235048.
21. Boilson BA, Kiernan TJ, Harbuzariu A, Nelson RE, Lerman A, Simari RD. Circulating CD34+ cell subsets in patients with coronary endothelial dysfunction. Nat Clin Pract Cardiovasc Med 2008, 5(8):489-496. 10.1038/ncpcardio1277, 2518072, 18578002.
22. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008, 31(6):1147-1155. 10.1291/hypres.31.1147, 18716362.
23. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009, 8:23. 10.1186/1475-2840-8-23, 2688503, 19402896.
24. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, Cannavan FP, Moreno H. Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol 2011, 10:24. 10.1186/1475-2840-10-24, 3072316, 21426540.
25. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007, 48(4):751-762. 10.1194/jlr.R600021-JLR200, 17202130.
26. Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005, 31(5-6):215-219.
27. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997, 15(1):3-17. 10.1097/00004872-199715010-00001, 9050965.
28. Eguchi K, Kario K, Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002, 25(3):329-333. 10.1291/hypres.25.329, 12135309.
29. Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 2007, 57(11):698-704.
30. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348(7):593-600. 10.1056/NEJMoa022287, 12584367.
31. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996, 5(3):213-226. 10.1089/scd.1.1996.5.213, 8817388.
32. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104(2):191-196.
33. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010, 31(9):1142-1148. 10.1093/eurheartj/ehq010, 20181680.
34. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57(5):1349-1354. 10.2337/db08-0063, 18299315.
35. Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, Fukushima Y, Kume A, Matsumori R, Sumiyoshi K, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J 2010, 74(7):1471-1478. 10.1253/circj.CJ-10-0013, 20519875.
36. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106(10):1211-1218. 10.1161/01.CIR.0000027569.76671.A8, 12208795.